Literature DB >> 16929387

Atrial fibrillation: challenges and opportunities.

Ahmad Hersi1, L Brent Mitchell, D George Wyse.   

Abstract

Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice. There are many pharmacological and nonpharmacological options available for AF patients. There is, however, a great deal of dissatisfaction with the available treatments of this arrhythmia. Furthermore, AF management remains associated with many challenges that make the treatment of AF a vexing problem. The present overview discusses these challenges and explores the opportunities associated with them.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16929387      PMCID： PMC2793882          DOI： 10.1016/s0828-282x(06)70998-9

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


  59 in total

Review 1.  Atrial fibrillation: a perspective: thinking inside and outside the box.

Authors:  D George Wyse; Bernard J Gersh
Journal:  Circulation       Date:  2004-06-29       Impact factor: 29.690

2.  Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction.

Authors:  Alawi A Alsheikh-Ali; Paul J Wang; William Rand; Marvin A Konstam; Munther K Homoud; Mark S Link; N A Mark Estes; Deeb N Salem; Amin M Al-Ahmad
Journal:  Am Heart J       Date:  2004-06       Impact factor: 4.749

3.  Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study.

Authors:  Scott D Corley; Andrew E Epstein; John P DiMarco; Michael J Domanski; Nancy Geller; H Leon Greene; Richard A Josephson; Joyce C Kellen; Richard C Klein; Andrew D Krahn; Mary Mickel; L Brent Mitchell; Joy Dalquist Nelson; Yves Rosenberg; Eleanor Schron; Lynn Shemanski; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2004-03-08       Impact factor: 29.690

4.  Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.

Authors:  Yinong Young-Xu; Samer Jabbour; Robert Goldberg; Charles M Blatt; Thomas Graboys; Brian Bilchik; Shmuel Ravid
Journal:  Am J Cardiol       Date:  2003-12-15       Impact factor: 2.778

5.  Analysis of cause-specific mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

Authors:  Jonathan S Steinberg; Ara Sadaniantz; Jack Kron; Andrew Krahn; D Marty Denny; James Daubert; W Barton Campbell; Edward Havranek; Katherine Murray; Brian Olshansky; Gearoid O'Neill; Magdi Sami; Stanley Schmidt; Randle Storm; Miguel Zabalgoitia; John Miller; Mary Chandler; Elaine M Nasco; H Leon Greene
Journal:  Circulation       Date:  2004-03-29       Impact factor: 29.690

6.  A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate.

Authors:  Koonlawee Nademanee; John McKenzie; Erol Kosar; Mark Schwab; Buncha Sunsaneewitayakul; Thaveekiat Vasavakul; Chotikorn Khunnawat; Tachapong Ngarmukos
Journal:  J Am Coll Cardiol       Date:  2004-06-02       Impact factor: 24.094

7.  Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation.

Authors:  Carlo Pappone; Vincenzo Santinelli; Francesco Manguso; Gabriele Vicedomini; Filippo Gugliotta; Giuseppe Augello; Patrizio Mazzone; Valter Tortoriello; Giovanni Landoni; Alberto Zangrillo; Christopher Lang; Takeshi Tomita; Cézar Mesas; Elio Mastella; Ottavio Alfieri
Journal:  Circulation       Date:  2004-01-05       Impact factor: 29.690

8.  Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation.

Authors:  Carlo Pappone; Hakan Oral; Vincenzo Santinelli; Gabriele Vicedomini; Christopher C Lang; Francesco Manguso; Lucia Torracca; Stefano Benussi; Ottavio Alfieri; Robert Hong; William Lau; Kirk Hirata; Neil Shikuma; Burr Hall; Fred Morady
Journal:  Circulation       Date:  2004-05-24       Impact factor: 29.690

9.  Inflammation as a risk factor for atrial fibrillation.

Authors:  Ronnier J Aviles; David O Martin; Carolyn Apperson-Hansen; Penny L Houghtaling; Pentti Rautaharju; Richard A Kronmal; Russell P Tracy; David R Van Wagoner; Bruce M Psaty; Michael S Lauer; Mina K Chung
Journal:  Circulation       Date:  2003-11-17       Impact factor: 29.690

10.  Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.

Authors:  S Bertil Olsson
Journal:  Lancet       Date:  2003-11-22       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.